However, whereas the clinical implications of FLT3 and NPM1 mutations in de novo AML are largely well established, the impact of DNMT3A mutations on NPM1 and/or FLT3 mutations remains poorly understood especially in patients with AMLDNMT3A/FLT3/NPM1 [15,16]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.